Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
Provided By GlobeNewswire
Last update: May 7, 2025
CTIM-76 and CT-95 in Phase 1 Clinical Trials
Cash and cash equivalents of $89.4 million as of March 31, 2025
Company expects its cash and cash equivalents will continue to fund operations into 2027
Read more at globenewswire.com
